Protocols
http:www.bumc.bu.edu/clinicaltrials/
ACTIVE CUTANEOUS T-CELL LYMPHOMA PROTOCOLS
IRB #H-24264:Double-Blind Randomized, 2-Dose, Parellel Group, Multicenter Trial of HuMax-CD, a Fully Humananized Monoclonal Antibody (Anti-CD4) in Patients with Mycosis Fungoides Type CTCL (Stage IB-IVB) who are Refractory or Intolerant to Targretin and One Other Therapy
H-24290 Uvadex (Methoxsalen) Sterile Solutions in Conjunction with the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment of CTCL (Mycosis Fungoides) in Patients with TMN Classification Stage IA, IB, IIA (VERSION 1).
Novartis CLBH589B2201 / WIRB #20061584: A Phase II Study of Oral LBH589 in Adult Patients with Refractory Cutaneous T-Cell Lymphoma
ACTIVE MELANOMA PROTOCOLS
Advanced Disease:
IRB #H-25395/SWOG #S0438: A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma
Links:
